乙型和丙型肝炎
Hepatitis B and C.
作者信息
Karnsakul Wikrom, Schwarz Kathleen B
机构信息
Pediatric Liver Center, Department of Pediatrics, Johns Hopkins University School of Medicine, 600 North Wolfe Street, CMSC 2-117, Baltimore, MD 21287, USA.
Pediatric Liver Center, Department of Pediatrics, Johns Hopkins University School of Medicine, 600 North Wolfe Street, CMSC 2-116, Baltimore, MD 21287, USA.
出版信息
Pediatr Clin North Am. 2017 Jun;64(3):641-658. doi: 10.1016/j.pcl.2017.01.007.
Abstract
Chronic viral hepatitis is a global health threat and financial burden. Hepatitis B and C viruses (HBV and HCV) are the most common causes of chronic viral hepatitis in the United States. Most cases are asymptomatic before adulthood. Research has resulted in effective therapy for HCV and the promise of effective therapies for HBV. For HCV, therapy is pegylated interferon and ribavirin. Clinical trials with effective direct-acting antiviral agents are underway in pediatrics. For HBV, approved agents are alpha-interferon, lamivudine, adefovir, tenofovir, and entecavir. However, treatment seldom results in functional cure and more effective therapies are urgently needed.
摘要
慢性病毒性肝炎是一种全球性的健康威胁和经济负担。乙型和丙型肝炎病毒（HBV和HCV）是美国慢性病毒性肝炎最常见的病因。大多数病例在成年前没有症状。研究已经产生了针对HCV的有效疗法，并有望开发出针对HBV的有效疗法。对于HCV，治疗方法是聚乙二醇化干扰素和利巴韦林。有效的直接抗病毒药物的儿科临床试验正在进行中。对于HBV，已获批的药物有α干扰素、拉米夫定、阿德福韦、替诺福韦和恩替卡韦。然而，治疗很少能实现功能性治愈，因此迫切需要更有效的疗法。
相似文献
1
Hepatitis B and C.
Pediatr Clin North Am. 2017 Jun;64(3):641-658. doi: 10.1016/j.pcl.2017.01.007.
2
[Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
Orv Hetil. 2012 Mar 11;153(10):375-94. doi: 10.1556/OH.2012.29338.
3
Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Gastroenterology. 2009 Feb;136(2):496-504.e3. doi: 10.1053/j.gastro.2008.10.049. Epub 2008 Oct 29.
4
[Diagnostic, clinical and therapeutic implications of viral hepatitides in HIV-infected patients].
Enferm Infecc Microbiol Clin. 2006 Oct;24 Suppl 1:30-5. doi: 10.1157/13094276.
5
Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues.
J Gastroenterol Hepatol. 2014 Jan;29(1):26-30. doi: 10.1111/jgh.12421.
6
[Management of hepatitis B virus and hepatitis C virus infection in chronic kidney failure].
Nephrol Ther. 2015 Nov;11(6):507-20. doi: 10.1016/j.nephro.2015.06.002. Epub 2015 Sep 28.
7
Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection.
J Gastroenterol Hepatol. 2016 Apr;31(4):835-41. doi: 10.1111/jgh.13203.
8
Present and future management of viral hepatitis B and C in children.
Clin Res Hepatol Gastroenterol. 2020 Nov;44(6):801-809. doi: 10.1016/j.clinre.2020.02.010. Epub 2020 Mar 12.
9
Treatment predictors of a sustained virologic response in hepatitis B and C.
J Hepatol. 2008 Oct;49(4):634-51. doi: 10.1016/j.jhep.2008.07.013. Epub 2008 Jul 31.
10
Update on viral hepatitis: 2008.
Curr Opin Gastroenterol. 2009 May;25(3):180-5. doi: 10.1097/MOG.0b013e328324f478.
引用本文的文献
1
Role of hepatotropic viruses in promoting hepatocellular carcinoma-current knowledge and recent advances.
Med Oncol. 2025 Mar 17;42(4):111. doi: 10.1007/s12032-025-02674-9.
2
Liver fibrosis in children: a comprehensive review of mechanisms, diagnosis, and therapy.
Clin Exp Pediatr. 2023 Mar;66(3):110-124. doi: 10.3345/cep.2022.00367. Epub 2022 Dec 19.
3
Overview of the microbiota in the gut-liver axis in viral B and C hepatitis.
World J Gastroenterol. 2021 Nov 21;27(43):7446-7461. doi: 10.3748/wjg.v27.i43.7446.
4
Past and Future Perspectives for Hepatitis B and C in Pakistan.
Cureus. 2021 Aug 28;13(8):e17521. doi: 10.7759/cureus.17521. eCollection 2021 Aug.
5
Seroprevalence of Viral Hepatitis B and C among Blood Donors in the Northern Region of Riyadh Province, Saudi Arabia.
Healthcare (Basel). 2021 Jul 24;9(8):934. doi: 10.3390/healthcare9080934.
6
Evaluation of AT-752, a Double Prodrug of a Guanosine Nucleotide Analog with and Activity against Dengue and Other Flaviviruses.
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0098821. doi: 10.1128/AAC.00988-21. Epub 2021 Aug 23.
7
A Liver Biopsy Validation Pilot Study of Shear Wave Elastography, APRI, FIB-4, and Novel Serum Biomarkers for Liver Fibrosis Staging in Children With Chronic Viral Hepatitis.
Glob Pediatr Health. 2020 Jul 30;7:2333794X20938931. doi: 10.1177/2333794X20938931. eCollection 2020.
8
Frequency and Associated Risk Factors of Hepatitis B Virus and Hepatitis C Virus Infections in Children at a Hepatitis Prevention and Treatment Clinic in Lahore, Pakistan.
Cureus. 2020 May 2;12(5):e7926. doi: 10.7759/cureus.7926.
9
Effects of the Q80K Polymorphism on the Physicochemical Properties of Hepatitis C Virus Subtype 1a NS3 Protease.
Viruses. 2019 Jul 30;11(8):691. doi: 10.3390/v11080691.
10
Blood-borne viral infections in pediatric hemodialysis.
Pediatr Nephrol. 2019 Jun;34(6):1019-1031. doi: 10.1007/s00467-018-4019-y. Epub 2018 Jul 21.
本文引用的文献
1
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
Gastroenterology. 2016 Sep;151(3):501-512.e1. doi: 10.1053/j.gastro.2016.06.002. Epub 2016 Jun 11.
2
Long-Term Follow-Up of Children Treated With Peginterferon and Ribavirin for Hepatitis C Virus Infection.
J Pediatr Gastroenterol Nutr. 2017 Jan;64(1):89-94. doi: 10.1097/MPG.0000000000001239.
3
Hepatitis C Virus in Children: Deferring Treatment in Expectation of Direct-Acting Antiviral Agents.
Isr Med Assoc J. 2015 Nov;17(11):707-11.
4
Sexually transmitted diseases treatment guidelines, 2015.
MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137.
5
Vitamin D status and viral response to therapy in hepatitis C infected children.
World J Gastroenterol. 2015 Jan 28;21(4):1284-91. doi: 10.3748/wjg.v21.i4.1284.
6
Growth and development of children prenatally exposed to telbivudine administered for the treatment of chronic hepatitis B in their mothers.
Int J Infect Dis. 2015 Apr;33:97-103. doi: 10.1016/j.ijid.2014.09.002. Epub 2014 Oct 24.
7
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
Lancet. 2014 Nov 15;384(9956):1756-65. doi: 10.1016/S0140-6736(14)61036-9. Epub 2014 Jul 28.
8
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
Expert Rev Anti Infect Ther. 2014 Jul;12(7):763-73. doi: 10.1586/14787210.2014.929497.
9
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub 2014 Apr 11.
10
Rapid hepatitis C testing among persons at increased risk for infection--Wisconsin, 2012-2013.
MMWR Morb Mortal Wkly Rep. 2014 Apr 11;63(14):309-11.
Zotero 插件